Stay up to date with the latest developments from OpenBind – an initiative driving the future of structure-based drug design.
Explore our news, breakthroughs, and community updates as we accelerate innovation together.
May 5, 2026
Blog: Affinity and Kinetics Data in the EV‑A71 2A OpenBind Release
In this post, we describe how this first OpenBind data package was generated – from target selection and experimental design through large-scale structure and affinity data production – highlighting the scale, complexity, and rigor behind the final dataset.
May 5, 2026
Blog: OpenBind’s first release: A structure–affinity dataset for structure-based AI
This post presents OpenBind’s first structure-affinity data release for the EV A71 2A protease, alongside reference benchmarks and how the community can use and evaluate them.
May 5, 2026
Blog: Inside OpenBind’s First Public Data Release: The Real Process Behind the Data Generation
This post outlines the experimental and structural biology work underpinning OpenBind’s first data release, from protein production and crystallography through to model building and refinement.
May 5, 2026
OpenBind’s First Data and Model Release Marks a Milestone for AI‑Enabled Drug Discovery
The UK‑led OpenBind initiative has reached a major milestone with the release of its first publicly available dataset and predictive AI model – a groundbreaking step toward accelerating the discovery of new medicines using artificial intelligence.
March 2, 2026
OpenBind: delivering the UK’s AI for Science ambitions
The UK Government’s AI for Science Strategy and the UKRI AI Research and Innovation Strategic Framework set out an ambitious national agenda to accelerate discovery, strengthen global scientific leadership and translate AI‑enabled research into real‑world impact. The inclusion of OpenBind within these strategies reflects its role as a foundational capability helping to deliver this vision.
July 18, 2025
UK and France ministers back AI drug discovery at Diamond
The UK’s Parliamentary Under-Secretary of State at the Department of Science, Innovation and Technology, Feryal Clark, visited Diamond to gain insights into the groundbreaking work planned by the OpenBind consortium. An ambitious initiative that aims to revolutionise drug discovery through artificial intelligence. Feryal Clark, Parliamentary Under-Secretary of State for Science, Innovation and Technology, visited Diamond Light Source to learn about OpenBind – an AI-driven initiative set to transform drug discovery.
June 10, 2025
Diamond will host a pioneering AI-driven drug discovery consortium
Diamond will be the base for OpenBind, an AI-driven drug discovery centre which will make the UK a world-leader in drug innovation and advancement.
